Peanut Hypersensitivity clinical trials

The registry lists 166 studies for Peanut Hypersensitivity across more than 10 countries. 27 are recruiting or about to start. 139 of them are mainly about Peanut Hypersensitivity (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-09.

Get an email when these change. Save the Peanut Hypersensitivity studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 93
Recruiting: 18
Terminated: 14
Active, not recruiting: 13
Status unknown: 10
Withdrawn: 7

Phase

Phase 2: 59
Phase 1: 42
Phase 3: 20
Early Phase 1: 2
Phase 4: 1

Where

United States: 98
Canada: 29
France: 18
United Kingdom: 17
Australia: 14
Germany: 13

Who runs them

University of North Carolina, Chapel Hill (13) · DBV Technologies (13) · National Institute of Allergy and Infectious Diseases (NIAID) (12) · Aimmune Therapeutics, Inc. (10) · Johns Hopkins University (7) · Novartis Pharmaceuticals (5) · Massachusetts General Hospital (5) · University Hospital, Montpellier (4)

What is being tested here

Drugs under test in Peanut Hypersensitivity studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Remibrutinib	1	1	2
LP-003	1	0	1
Tezepelumab	1	0	1
Peanut	0	0	13
Palforzia	0	4	10
Omalizumab	0	1	7
Panobacumab	0	4	6
Iclaprim, (r)-	0	4	6
Dupilumab	0	0	3
Ligelizumab	0	2	3

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 1 open

Coming up

3phase 3 studies under way

11studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Nov 2026Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers) · Phase 3 · DBV Technologies
Nov 2026Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects · Allergy Therapeutics
Dec 2026Food Oral Immunotherapy for Peanut Allergy · Massachusetts General Hospital
Dec 2026Understanding the Immune System's Role in Tree Nut and Peanut Allergies: Key Biomarkers for Diagnosis and Treatment Monitoring and Treatment Targets · Luxembourg Institute of Health
Jan 2027A Long Term, Observational Follow-Up Study of Children and Young People Who Underwent an 18-Month Course of Oral Immunotherapy Treatment for Peanut, Egg or Milk Allergy (5-15 Years Post-Treatment) · Murdoch Childrens Research Institute
Jan 2027Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients · Rima Rachid
Mar 2027Predictors of Persistent Peanut Allergy at Age 5 Years · University of Manitoba
Mar 2027UKK-0018 as an Immunotherapeutic for Treatment of Peanut Allergies · Ukko Inc
Mar 2027Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy · RAPT Therapeutics, Inc., a member of the GSK plc group of companies
Apr 2027Study to Evaluate the Safety, Pharmacokinetic, and Pharmacodynamic Effects of MY006 in Healthy Volunteers and Patients With Peanut Allergy · Mabylon AG

Who these studies take

Of the 18 Peanut Hypersensitivity studies recruiting now, 2 (11%) set no upper age limit and 16 (89%) stop at 75 or younger. 15 (83%) take children under 18. 1 (6%) are for women only and 0 (0%) for men only; 6 (33%) take healthy volunteers.

Recruiting studies that take each age, of 18
Age	Women	Men
10	8 (44%)	7 (39%)
18	13 (72%)	12 (67%)
30	13 (72%)	12 (67%)
40	13 (72%)	12 (67%)
50	12 (67%)	11 (61%)
65	6 (33%)	5 (28%)
75	3 (17%)	2 (11%)
85	2 (11%)	1 (6%)

Across all 166 studies, recruiting or not: 88% stop at 75 or younger and 86% at 65; 84% take children; 1% are for women only and 0% for men only; 17% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Peanut Hypersensitivity studies take

Of 18 phase 2 interventional studies under Peanut Hypersensitivity, half reached primary completion within 31 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 1	25 mo16–52 · 14 studies	—	—
Phase 2	31 mo23–58 · 18 studies	—	—
Phase 3	29 mo23–42 · 15 studies	—	—
Interventional, no phase	62 mo31–66 · 20 studies	—	—

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 11, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 166. Browse all 166 → or search them.